louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01979237: Comparing FARES Method With SPASO Method for Reduction of Anterior Shoulder Dislocation: a Prospective Randomized Trial
Official title: Comparing FARES Method With SPASO Method for Reduction of Anterior Shoulder Dislocation: a Prospective Randomized Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Shoulder Anterior Dislocation
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2013-11-08
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Shoulder anterior dislocation is a major disease entity in emergency department. There are more than 10 reduction methods that have been reported. Traditional reduction methods require sedatives, which could cause adverse effects on the patients such as respiratory suppression and allergy. There are some reduction maneuvers reported recently which do not need sedatives prior to performing reduction, including FARES method and SPASO method. So far, there are no well-designed study to compare these two methods. Besides, in clinical experience, we found that combining these two methods could even get higher successful reduction rate. This study is aimed to compare these two methods as a prospective randomized design, and furthermore, to show that combining these two methods could get higher successful reduction rate.


Eligibility criteria: Inclusion Criteria:

* shoulder anterior dislocation
* conscious clear
* communicable

Exclusion Criteria:

* unconscious
* non-communicable
* humeral neck fracture
* dislocation time \> 24 hours
* neurovascular compromise

Primary outcomes:
measure: Successful reduction rate
timeFrame: Less than 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital (NTUH)
Study officials:
References:
Clinical trial NCT02878915: Ultrasound-guided Femoral Arterial Puncture for Interventional Neuro-radiology in Children
Official title: Assessing the Interest of Ultrasound-guided Femoral Arterial Puncture for Interventional Neuro-radiology in Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Retrograde Femoral Catheterism
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2016-08-25
Enrollment: 150
Sex: ALL
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Using ultrasound to guide vascular catheterism in children is highly recommended for central venous access. It has been proven that central venous line is inserted faster, with fewer attempts and complications. Its interest in central arterial line insertion is less obvious. It seems to have benefits in adults, both for radial and femoral arterial insertion. But there is no study assessing the interest of ultrasound guided arterial puncture in children,.

Detailed description: The use of ultrasound to guide vascular catheterization in children is strongly recommended for central venous vascular access by several international learned societies. In fact, studies have found a reduction in the time it takes to install the central venous line, in the number of attempts and in complications.The benefit of ultrasound to guide catheterization of the arterial network is less documented.

In children, there is an inventory of the traditional approach guided by palpation, in children in intensive care (11). The analysis of 77 femoral puncture attempts in 74 children was carried out. Arterial cannulation was successful in 73 of 77 cases (95%), but only in 60% of cases at the first attempt. Ultrasound guidance appears beneficial in adults for both arterial sites, radial and femoral. On the other hand, in children, unlike radial catheterization, there is no study evaluating the contribution of ultrasound guidance for femoral catheterization.

Eligibility criteria: Inclusion Criteria:

* requirement of retrograde femoral arterial catheterism

Exclusion Criteria:

* none

Primary outcomes:
measure: Demonstrate that ultrasound guidance improves the success rate at the 1st attempt
timeFrame: immediate
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Fondation Ophtalmologique Adolphe de Rothschild
Study officials:
affiliation: Fondation Ophtalmologique Adolphe de Rothschild
name: Raphaël Blanc, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00571415: Image-guided Adaptive Radiotherapy for Cervix Cancer: Patient Image Acquisition
Official title: Image-guided Adaptive Radiotherapy for Cervix Cancer: Patient Image Acquisition
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Cervix Cancer
Keywords: Image guided adaptive radiotherapy
Lead sponsor: Virginia Commonwealth University
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2007-12-12
Enrollment: 21
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: University hospital clinic

Brief summary: Within this study patient data are collected from different imaging and motion monitoring devices that will be used to develop and test strategies for image-guided adaptive radiotherapy in cervix cancer patients.


Eligibility criteria: Inclusion Criteria:

* Histological diagnosis of cervix cancer
* Prescription of radiation treatment to the primary cancer

Exclusion Criteria:

* Prior radiation treatment to the pelvis

Primary outcomes:
measure: Increase in therapeutic ratio
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Richmond
country: United States
facility: Viriginia Commonwealth University, Department of Radiation Oncology
state: Virginia
Study officials:
affiliation: Virginia Commonwealth University, Department of Radiation Oncology
name: Jeffrey F Williamson, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: VCU, Richmond, VA
name: Jeffrey F Williamson, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03917615: Pelvic Floor Muscle Contraction Among Physiotherapy Students Before and After "Women Health" Course
Official title: Pelvic Floor Muscle Contraction Among Physiotherapy Students Before and After "Women Health" Course
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pelvic Floor Muscle Weakness
Keywords: pelvic diaphragm, Physiotherapy students, education
Lead sponsor: University of Haifa
Sponsor class: OTHER
First posted: 2019-04-17
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 2 groups according to the year of physiotherapy school.
Primary purpose: SCREENING

Brief summary: The study aim is to evaluate the ability to correctly contract pelvic floor muscle among physiotherapy students before and after "women health" course. Pelvic floor muscle contraction will be evaluated via transabdominal ultrasound.

Detailed description: Physiotherapy students during their studying in the physiotherapy Bachelor degree program will be examined. Students will be divided into 2 groups according to their year of studying (if they already studied "women health course or not implying 4th year students compared with 1-3 year level students). Each participant will be asked to contract the pelvic floor muscles.

The assessment of pelvic floor contraction will be measured by measuring bladder displacement via abdominal ultrasound. A curved linear array transducer will be placed in the transverse plane immediately suprapubically over the lower abdomen angled at 15-30 degrees from the vertical. Upward movement of the bladder during contraction will be marked as correct contraction. An on screen caliper and measurement tool will be used to measure bladder amount of bladder displacement.

Eligibility criteria: Inclusion Criteria:

* healthy students
* willing to participate in the study

Exclusion Criteria:

* has been treated before for pelvic floor rehabilitation
* active urinary tract infection
* pregnancy
* previous abdominal surgeries

Primary outcomes:
measure: direction of urinary bladder displacement during contraction
timeFrame: baseline
measure: urinary bladder displacement in millimeters
timeFrame: baseline
Secondary outcomes:
measure: pelvic floor muscles endurance of contraction in seconds
timeFrame: baseline
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Haifa University, Department of PHysical Therapy
Study officials:
affiliation: University of Haifa
name: Gali Dar, PhD
role: STUDY_DIRECTOR
References:
citation: Ben Ami N, Dar G. What is the most effective verbal instruction for correctly contracting the pelvic floor muscles? Neurourol Urodyn. 2018 Nov;37(8):2904-2910. doi: 10.1002/nau.23810. Epub 2018 Aug 28.
Clinical trial NCT04801615: Characteristics of Patients With Necrotizing Soft Tissue Infections
Official title: Demographic Characteristics, Symptoms, Treatment and Mortality of Patients With Necrotizing Soft Tissue Infections
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Necrotizing Soft Tissue Infection
Lead sponsor: Aarhus University Hospital
Sponsor class: OTHER
First posted: 2021-03-17
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients admitted to Aarhus University Hospital with necrotizing soft tissue infections, either diagnosed prior to arriving to the hospital or diagnosed in the hospital.

Brief summary: To study the demographic characteristic of patients with necrotizing soft tissue infections.

Detailed description: At Aarhus University Hospital, Denmark, all patients with necrotizing soft tissue infections will be registered in a database in order to be able to describe their symptoms, demographic variables and thier treatment (surgery, time to surgery, antibiotics, intensive care unit, laboratory data etc).

Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with necrotizing soft tissue infections and treated at Aarhus Universital Hospital

Primary outcomes:
measure: Percentage of patients that dies within 1 year following admission date
timeFrame: 12 months following admission date
Secondary outcomes:
Other outcomes:
Locations:
city: Aarhus N
country: Denmark
facility: Aarhus University Hospital
Study officials:
affiliation: Aarhus University Hospital
name: per gundtoft
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00311415: Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children
Official title: A Phase III, Multi-Center, Open-Label, Controlled, Randomized Study to Evaluate the Immunogenicity, Safety, Tolerability and the Ability to Prime for Memory of Chiron Meningococcal C Conjugate Vaccine When Administered to Healthy Infants as One Dose Given at 2 or 6 Months of Age With a Booster at 12-16 Months of Age, in Comparison to Two Doses in the First Year of Life, Given Two Months Apart, With a Booster at 12-16 Months of Age; and in Comparison to One Dose Given at 12-16 Months of Age
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Prevention of Meningococcal Infection
Keywords: Prevention of Meningococcal Meningitis
meningococcal vaccines
conjugate
immunology
infant
antibody persistence
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2006-04-06
Enrollment: 257
Sex: ALL
Minimum age (years): 7
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in healthy children

Detailed description: The aim of this study is to investigate the immunogenicity offered by MenCC vaccine when administered in different schedules at different years of life: 2 doses in the first year of life given 2 months apart (at 2 and 4 months of age), with a booster in the second year of life, or 1 dose in the first year of life (at 2 or 6 months of age), with a booster in the second year of life, or only 1 dose in the second year of life.

Eligibility criteria: Inclusion Criteria:

* healthy infants

Exclusion Criteria:

* known hypersensitivity to any vaccine component
* significant acute or chronic infections
* previously ascertained or suspected disease caused by N. meningitidis
* previous household contact with an individual with a positive culture of N. meningitidis serogroup C

Primary outcomes:
measure: Demonstration of non-inferiority of memory antibody response after 1 dose of MenC Vaccine administered to healthy infants at 2 to 6 months of age and as first, second or third dose in the second year of life,as measured by rBCA.
timeFrame: Overall study period
Secondary outcomes:
measure: Evaluation and comparison of antibody response and its persistence in terms of GMT and percent responders, as measured by rBCA.
timeFrame: Overall study period
Other outcomes:
Locations:
city: Mainz, Kehl, Neumünster, Ettenheim
country: Germany
city: Kraków, Lubartów, Lublin, Bydgosczcz
country: Poland
Study officials:
affiliation: Novartis Vaccines & Diagnostics
name: Novartis Vaccines - Information Services
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02244515: Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy
Official title: Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Emergence Deliruim; Cerebral Palsy
Keywords: children
Lead sponsor: Guangzhou Women and Children's Medical Center
Sponsor class: OTHER
First posted: 2014-09-19
Enrollment: 80
Sex: ALL
Minimum age (years): 2
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine whether dexmedetomidine is effective in the treatment of emergence deliruim after sevoflurane anesthesia in children with cerebral palsy.


Eligibility criteria: Inclusion Criteria:

Non-quadriplegic (mono-,di-, hemiplegic) children with CP that are scheduled for elective Achilles-tendon lengthening procedure Guangzhou Women and Children's Medical Center, Guangzhou, China, with American Society of Anesthesiologists (ASA) physical status I or II.

Exclusion Criteria:

Participants that displayed symptoms of sinus bradycardia and atrio-ventricular block, non-communicative severe developmental delay, seizure disorders, and treatment with seizure medications

Primary outcomes:
measure: pediatric anesthesia emergence delirium (PAED) scale
timeFrame: during stay in postanesthesia care unit
measure: Heart rate
timeFrame: during surgical procedures
measure: systolic blood pressure
timeFrame: during surgical procedures
measure: diastolic blood pressure
timeFrame: during surgical procedures
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00606515: Pharmacokinetics Study of Liposomal Paclitaxel in Humans
Official title: A Clinical Trial to Compare the Pharmacokinetics of Two Formulations of Taxane, Paclitaxel Injection and Liposomal Paclitaxel, in Humans
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cancer
Keywords: Pharmacokinetics
Liposomal paclitaxel
Lead sponsor: Shandong Luye Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Nanjing Sike Pharmaceutical Co., Ltd.
First posted: 2008-02-04
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this study is to determine whether there is any difference of the pharmacokinetics of two taxane formulations, paclitaxel injection and liposomal paclitaxel in Chinese cancer patients with solid tumors.

Detailed description: The pharmacokinetics of a new formulation of taxane (liposomal paclitaxel) has never been studied in Chinese cancer patients. This clinical trial is designed to find out the pharmacokinetics of liposomal paclitaxel at the dose of 175mg/m2 and whether it has a different pharmacokinetic profile to paclitaxel.

Eligibility criteria: Inclusion Criteria:

* Eligible patients must have histologically confirmed solid tumors of advanced stages
* Patients who are suitable for being treated with liposomal paclitaxel only
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
* Patients who are expected to be alive for at least 3 months
* Adequate hematologic, hepatic and renal functions
* Adequate other organ functions as defined by the protocol
* No prior systemic chemotherapy at least 4 weeks before the recruitment
* No previous anaphylactic reaction to hormone.

Exclusion Criteria:

* Allergy to any study medication
* Serious complication that would compromise the patient's ability to complete the study
* Grade ≥1 neuropathy using NCI CTCAE version 3.0 criteria
* Pregnancy or breast feeding

Primary outcomes:
measure: Pharmacokinetic parameters
timeFrame: 72 hours after the infusion
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Cancer Hospital of Fudan University
state: Shanghai
city: Shanghai
country: China
facility: Cancer Hospital of Fudan University
Study officials:
affiliation: Cancer Hospital of Fudan University
name: Jin Li, Doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06152315: Mitral Splay Sign, Its Mechanism and Association With Severity of Regurgitation
Official title: Study of Splay Sign in Mitral Regurgitation and Other Valve Lesions as Related to Its Mechanisms, Predictors of Its Occurence and Association With Severity of Mitral Regurgitation
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Mitral Regurgitation
Keywords: echocardiography
splay sign
seagull cry
Lead sponsor: ITMO University
Sponsor class: OTHER
First posted: 2023-11-30
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients referred to echocardiography in community hospital in Tarusa

Brief summary: To study echocardiography splay sign in mitral regurgitation and its association with mitral regurgitation severity and doppler band artifact ('seagull cry').


Eligibility criteria: Inclusion Criteria:

* any patient undergoing echocardiography for clinical indications

Exclusion Criteria:

* poor quality of recorded echocardiography study
* inability to ascertain severity of mitral regurgitation

Primary outcomes:
measure: Presence of mitral splay sign
timeFrame: 1 year
measure: Presence of narrow doppler bands
timeFrame: 1 year
Secondary outcomes:
measure: Mitral regurgitation severity
timeFrame: 1 year
Other outcomes:
measure: Blood pressure
timeFrame: 1 year
measure: Age
timeFrame: 1 year
measure: Gender
timeFrame: 1 year
measure: BMI
timeFrame: 1 year
Locations:
city: Tarusa
country: Russian Federation
facility: Tarusa Hospital
state: Kaluga Region
Study officials:
References:
Clinical trial NCT00473915: Intranasal Steroids and the Nasal Ocular Response
Official title: Intranasal Steroids Prevent Antigen-Induced Hyperresponsiveness of the Nasal Ocular Response
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Seasonal Allergic Rhinitis
Lead sponsor: University of Chicago
Sponsor class: OTHER
Collaborators: name: GlaxoSmithKline
First posted: 2007-05-16
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Eye symptoms of tearing, redness and itch frequently occur in patients with allergic rhinitis or hayfever. The purpose of this study is to learn whether placing allergen (the substance that causes allergies) in the nose several days in a row will cause an increase in eye symptoms and whether receiving a nasal steroid spray will prevent these eye symptoms.


Eligibility criteria: Inclusion Criteria

1. Males and females between 18 and 45 years of age.
2. History of grass and/or ragweed allergic rhinitis.
3. Positive skin test to grass and/or ragweed antigen.
4. Positive response to screening nasal challenge.

Exclusion Criteria

1. Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.
2. Pregnant or lactating women.
3. Upper respiratory infection within 14 days of study start.

Primary outcomes:
measure: Change in ocular symptoms
timeFrame: between days 1 and 3
Secondary outcomes:
measure: number of eosinophils
timeFrame: between days 1 and 3
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
Study officials:
affiliation: University of Chicago
name: Robert m Naclerio, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Baroody FM, Shenaq D, DeTineo M, Wang J, Naclerio RM. Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms. J Allergy Clin Immunol. 2009 Jun;123(6):1342-8. doi: 10.1016/j.jaci.2009.03.015. Epub 2009 May 9.